Chemical hepatocarcinogenesis in transgenic mice overexpressing mature TGFβ-1 in liver

European Journal of Cancer

Volumn 35, Issue 13, 1999, Pages 1842-1845

  Schnur, J ^a   Nagy, P ^b   Sebestyen A ^a   Schaff, Z ^b   Thorgeirsson, S S ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

2 acetylaminofluorene; Aflatoxin B1; Carcinogens; Mice; Thioacetamide; Transforming growth factor beta; Transgenic

Indexed keywords

AFLATOXIN B1; CARCINOGEN; FLUORENE DERIVATIVE; THIOACETAMIDE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; LIVER; LIVER CARCINOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

2-ACETYLAMINOFLUORENE; AFLATOXIN B1; ANIMALS; CARCINOGENS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 0032739624     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00224-5     Document Type: Article

References (30)

1. Alevizopoulos A, Mermod N. Transforming growth factor-β: the breaking open of a black box. Bio Essays 1997, 19, 581 -591.
2. Nagy P, Evarts RP, McMahon JB, Thorgeirsson SS. Role of TGF-beta in normal differentiation and oncogenesis in rat liver. Mol Cardnogenesis 1989, 2, 345-354.
3. Factor VM, Kao Ch, Santoni-Rugiu E, Woitach JT, Thorgeirsson SS. Constitutive expression of mature transforming growth factor β1 in the liver accelerates hepatocarcinogenesis in transgenic mice. Cancer Res 1997, 57, 2089-2095.
4. Glick AB, Kulkarni AB, Tennenbaum T, et al. Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc Natl Acad Sei USA 1993, 90, 6076-6080.
5. Böttinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield M. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-Dimethylbenz-(alpha)-anthracene. Cancer Res 1997,57, 5564-5570.
6. Sanderson N, Factor VM, Nagy P, et al. Hepatic expression of mature transforming growth factor βl in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sei USA 1995, 92, 2572-2576.
7. Kopp JB, Factor VM, Mozes M, et al. Transgenic mice with increased plasma levels of TGF-βl develop progressive renal disease. Lab Invest 1996, 74, 991-1003.
8. Bhide SV. Studies on progressive metabolic alterations in thioacetamide induced hepatocarcinogenesis. Br J Cancer 1970, 24, 504-509.
9. Manam S, Shinder GA, Joslyn DJ, et al. Dose-related changes in the profile of ras mutations in chemically induced CD-1 mouse liver tumors. Cardnogenesis 1995, 16, 1113-1119.
10. Bauer-Hofmann R, Buchmann A, Wright AS, Schwarz M. Mutations in the Ha-ras proto-oncogene in spontaneous and chemically induced liver tumors of the CF1 mouse. Cardnogenesis 1990, 11, 1875-1877.
11. Frith GH, Ward JM. A morphologic classification of proliferative and neoplastic hepatic lesions in mice. J Environ Pathol and Toxicol 1980, 3, 329-351.
12. Sieweke MH, Thompson NL, Sporn MB, Bissell MJ. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-. Science 1990, 248, 1656-1660.
13. Akhurst RJ, Fee F, Baimain A. Localized production of TGF-β mRNA in tumour promoter-stimulated mouse epidermis. Nature 1988,331,363-365.
14. Sieweke MH, Bissell MJ. The tumor promoting effect of wounding: a possible role for TGF-β-induced stromal alterations. Crit Rev Oncogenesis 1994, 5, 297-311.
15. Braun L, Gruppuso P, Mikumo R, Fausto N. Transforming growth factor βl in liver carcinogenesis: messenger RNA expression and growth effects. Cell Growth Diff 1990, 1, 103-111.
16. Ohlson LCE, Koroxenidou L, Hällström IP. Inhibition of in vivo rat liver regeneration by 2-acetylaminofluorene affects the regulation of cell cycle-related proteins. Hepatology 1998, 27, 691-696.
17. Barbason H, Rassenfosse C, Betz EH. Promotion mechanism of phénobarbital and partial hepatectomy in DENA hepatocarcinogenesis: cell kinetic effects. Br J Cancer 1983, 47, 517-525.
18. Sheik A, Yusuf A, Laconi E, Pao PM, Rajalaksmi S, Sarma DSR. Effects of orotic acid on in vivo DNA sythesis in hepatocytes of normal rat liver and in hepatic foci/nodules. Carcinogenesis 1993, 14,907-912.
19. Tanaka K, Smith PF, Stromberg PC, et al. Studies of early hepatocellular proliferation and peroxisomal proliferation in Sprague-Dawley rats treated with tumorigenic doses of clofibrate. Toxicol Appl Pharmacol 1992, 116, 71-77.
20. Bedossa O, Peltier E, Terris B, Franco D, Poynard T. Transforming growth factor-beta l (TGF-β 1) and TGF-β l receptors in normal, cirrhotic and neoplastic human livers. Hepatology 1995,21, 760-766.
21. Orsatti G, Hytiroglou P, Thung SN, Ishak KG, Paronetto F. Lamellar fibrosis in the fibrolamellar variant of hepatocellular carcinoma: a role for transforming growth factor beta. Liver 1997, 17, 152-156.
22. Vogelbruch M, Wellmann A, Maschek H, Schafer MK, Flemming P, Georgii A. Transforming growth factor beta 1 in human liver tumors. Verhandlungen der Deutschen Gesellschaft für Pathologie 1995, 79, 132-136.
23. Sue SR, Chari RS, Kong FM, et al. Transforming growth factor beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma. Ann Surg 1995, 222, 171-178.
24. Wollenberg GK, Semple E, Quinn BA, Hayes MA. Inhibition of proliferation of normal, preneoplastic and neoplastic hepatocytes by transforming growth factor-βl. Cancer Res 1987, 47, 6595-6599.
25. Tang B, Böttinger EP, Jakowlew SB, et al. Transforming growth factor-beta 1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 1998, 4, 802-807.
26. Massey TE, Stewart RK, Daniels JM, Liu I. Biochemical and molecular aspects of mammalian susceptibility to aflatoxin B l carcinogenity. Proc Soc Exp Biol Med 1995, 208, 213-227.
27. Glick AB, Weinberg WC, Wu IH, Quan W, Yuspa SH. Transforming growth factor βl suppresses genomic instability independent of a G, arrest, p53, and Rb. Cancer Res 1996, 56, 36453650.
28. Miller EC. Some current perspectives on chemical carcinogenesis in humans and experimental animals: presidential address. Cancer Res 1978, 38, 1479-1496.
29. Wogan GN, Newberne GM. Dose-response characteristics of aflatoxin Bl carcinogenesis in the rat. Cancer Res 1967, 27, 2370-2376.
30. Becker FF. Thioacetamide hepatocarcinogenesis. J Nat Cancer Inst 1983, 71, 553-558.